Non-Antibody Products — page 1 of 97,649
Non-Antibody Products
Page 1 of 97,649
| Name | Description | Size | Catalog # | Supplier | |
|---|---|---|---|---|---|
| A77 1726 | Purity ≥98% by HPLC. Background: Physiologically active metabolite of t… | 5 mg, 25 mg | MBS842963 |
 MYBIOSOURCE INC. |
More Info |
| A77-01 | Purity ≥98%. MW: 286.33 | 2 mg, 5 mg, 1ml/10mM (in DMSO) | MBS577536 |
MYBIOSOURCE INC. |
More Info |
| A77-01 | Purity ≥98%. MW: 286.338 | 100 mg, 500 mg | MBS130865 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98% (TLC). MW: 357.8 | 10 mg, 50 mg | MBS565381 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98% by TLC. Background: A-803467 is a potent, selective inhibit… | 5 mg, 25 mg | MBS842200 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98%. MW: 357.79 | 100 mg, 500 mg | MBS132100 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98%. MW: 357.79 | 1ml/10mM (in DMSO), 10 mg, 25 mg | MBS575739 |
MYBIOSOURCE INC. |
More Info |
| A-804598 | Purity >98%. A-804598 is a P2X7 selective, competitive antagonist with the… | 5 mg, 10 mg, 25 mg | MBS384094 |
MYBIOSOURCE INC. |
More Info |
| A83-01 | Purity >98% (TLC); NMR (Conforms). ALK inhibitor. Selective glycogen synth… | 5 mg, 25 mg | MBS515040 |
MYBIOSOURCE INC. |
More Info |
| A-83-01 | Purity 97%+. MW: 421.52 | 2 mg, 5 mg, 10 mg | MBS575483 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | A-966492 is a highly potent and efficacious poly(ADP-ribose) polymerase (P… | 10 mg | MBS8506196 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | Purity ≥98%. A-966492 is a novel and potent inhibitor of PARP1 and PARP… | 2 mg, 5 mg, 1ml/10mM (in DMSO) | MBS578914 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | Purity ≥98%. MW: 324.359 | 100 mg, 500 mg | MBS132689 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | Purity >98%. A-966492 displayed high potency against the poly(ADP-ribose)… | 5 mg, 1 mL (in DMSO), 10 mg | MBS384096 |
MYBIOSOURCE INC. |
More Info |
| 293A | The HEK 293A cell line is an immortalized line of primary human embryonic… | 1 vial | ABI-TC1333 |
 ACCEGEN BIOTECH |
More Info |
| A10.7 | Species: human. Derived from metastatic liver tumor (clinical stage IV). | 1 vial | ABC-TC533S |
ACCEGEN BIOTECH |
More Info |
| A-172 | Species: human. Organ: brain Disease: glioblastoma. | 1 vial | ABC-TC0022 |
ACCEGEN BIOTECH |
More Info |
| A-204 | Human Muscle Rhabdomyosarcoma cell line. The A-204 cell line was establish… | 1 vial | ABC-TC445S |
ACCEGEN BIOTECH |
More Info |
| A2058 | Species: human. Malignant melanoma, metastasis to lymph node. | 1 vial | ABC-TC0023 |
ACCEGEN BIOTECH |
More Info |
| A-253 | The A253 line is one of thirteen to be isolated and partially characterize… | 1 vial | ABC-TC0024 |
ACCEGEN BIOTECH |
More Info |
| A375 | Species: human. This line was derived from a 54 year old female with malig… | 1 vial | ABC-TC0026 |
ACCEGEN BIOTECH |
More Info |
| A-427 | Species: human. A-427 cell line was established from the lung carcinoma of… | 1 vial | ABC-TC1339 |
ACCEGEN BIOTECH |
More Info |
| A-431 | Species: human. The epidermoid carcinoma cell line A-431, derived from an… | 1 vial | ABC-TC0030 |
ACCEGEN BIOTECH |
More Info |
| A-498 | Species: human. Established from the kidney carcinoma of a 52-year-old man… | 1 vial | ABC-TC0031 |
ACCEGEN BIOTECH |
More Info |
| A549 | Species: human. A549 cell line was initiated in 1972 by D.J. Giard, et al.… | 1 vial | ABC-TC0032 |
ACCEGEN BIOTECH |
More Info |